Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: Statistical power of parallel-groups and crossover designs

[1]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[2]  Roland Martin,et al.  Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis , 1992, Annals of neurology.

[3]  F. Barkhof,et al.  Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. , 1992, AJR. American journal of roentgenology.

[4]  A. Thompson,et al.  Serial gadolinium‐enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration , 1992, Neurology.

[5]  A. Thompson,et al.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[6]  N. Patronas,et al.  Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing‐remitting multiple sclerosis: Implications for clinical trials and natural history , 1991, Annals of neurology.

[7]  A. Thompson,et al.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis , 1991, Annals of neurology.

[8]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[9]  D. Wolinsky,et al.  Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double‐blinded, placebo‐controlled clinical trial , 1990 .

[10]  D. Li,et al.  Chronic progressive multiple sclerosis: Serial magnetic resonance brain imaging over six months , 1989, Annals of neurology.

[11]  D. Li,et al.  Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patients , 1989, Annals of neurology.

[12]  D. Li,et al.  Benign versus chronic progressive multiple sclerosis: Magnetic resonance imaging features , 1989, Annals of neurology.

[13]  J. Oger,et al.  Multiple sclerosis , 1988, Neurology.

[14]  J. Fleiss.  The design and analysis of clinical experiments , 1987 .

[15]  R. Hohlfeld,et al.  Myasthenia gravis: Reactivation of clinical disease and of automimmune factors after discontinuation of long‐term azathioprine , 1985, Annals of neurology.

[16]  P. Spencer,et al.  Clinical and experimental neurotoxicity of 2‐t‐butylazo‐2‐hydroxy‐5‐methylhexane , 1985, Annals of neurology.

[17]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[18]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[19]  B. Kirkwood.  Essentials of medical statistics. , 1988 .